# Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC).

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/randomized-placebo-controlled-phase-iii-trial-of-sunitinib-in-combination-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yang Ou,M. Dror Michaelson,L. Sengeløv,Farid Saad,Nadine Houédé,Peter Ostler,A. Stenzl,Gedske Daugaard,Robert J. Jones,F. Laestadius,Amit Bahl,Daniel Castellano,J. Gschwend,Tristan Maurina,D. Ye,I. Chen,S. Wang,Edna Chow Maneval,Stéphane Oudard |
| Citations | 56 |
| DOI | 10.1200/jco.2011.29.15_suppl.4515 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2590079277 |
| Type | conference-abstract |
| Year | 2011 |

## Paper authors

- [Yang Ou](https://scholariq.org/researchers/yang-ou/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)

## Paper topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.